MA53920A - Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 - Google Patents

Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38

Info

Publication number
MA53920A
MA53920A MA053920A MA53920A MA53920A MA 53920 A MA53920 A MA 53920A MA 053920 A MA053920 A MA 053920A MA 53920 A MA53920 A MA 53920A MA 53920 A MA53920 A MA 53920A
Authority
MA
Morocco
Prior art keywords
antibodies
subcutaneous administration
providing subcutaneous
providing
administration
Prior art date
Application number
MA053920A
Other languages
English (en)
Inventor
Kim Anne Campbell
Ivo Nnane
Donald Raible
Cathye Shu
Zhenhua Xu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA53920A publication Critical patent/MA53920A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053920A 2018-10-17 2019-10-17 Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 MA53920A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862747107P 2018-10-17 2018-10-17

Publications (1)

Publication Number Publication Date
MA53920A true MA53920A (fr) 2021-09-15

Family

ID=68531583

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053920A MA53920A (fr) 2018-10-17 2019-10-17 Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38

Country Status (11)

Country Link
US (1) US20200121588A1 (fr)
EP (1) EP3867275A2 (fr)
JP (1) JP2022512722A (fr)
KR (1) KR20210077725A (fr)
CN (1) CN113195540A (fr)
AU (1) AU2019362868A1 (fr)
BR (1) BR112021007227A2 (fr)
CA (1) CA3116878A1 (fr)
MA (1) MA53920A (fr)
MX (1) MX2021004465A (fr)
WO (1) WO2020081881A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN116635422A (zh) * 2021-01-14 2023-08-22 莫佛塞斯公司 抗cd38抗体及其用途
EP4277930A1 (fr) * 2021-01-14 2023-11-22 MorphoSys AG Anticorps anti-cd38 et leurs utilisations
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
US20240197783A1 (en) * 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
US20230134748A1 (en) * 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2025160986A1 (fr) * 2024-02-02 2025-08-07 Keymed Biosciences (Chengdu) Co., Ltd. Anticorps monoclonal anti-cd38 et son application

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP2330213A1 (fr) 2003-03-05 2011-06-08 Halozyme, Inc. Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant
EP2915820A1 (fr) 2004-02-06 2015-09-09 MorphoSys AG Anticorps humains anti-CD38 et utilisations de ceux-ci
EP2551282A3 (fr) 2005-03-23 2013-02-13 Genmab A/S Anticorps diriges contre CD38 pour le traitement du myelome multiple
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
BR112014010532A2 (pt) * 2011-11-03 2017-04-18 Tolera Therapeutics Inc anticorpo e métodos para inibição seletiva de respostas de célula-t
CA2909952C (fr) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anticorps anti-cd38 et fusions sur un interferon alpha-2b attenue
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
US10556948B2 (en) * 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
CA3095086A1 (fr) * 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Administration sous-cutanee d'anticorps anti-cd38

Also Published As

Publication number Publication date
KR20210077725A (ko) 2021-06-25
AU2019362868A1 (en) 2021-05-13
EP3867275A2 (fr) 2021-08-25
MX2021004465A (es) 2021-08-24
CA3116878A1 (fr) 2020-04-23
WO2020081881A3 (fr) 2020-05-22
BR112021007227A2 (pt) 2021-08-10
WO2020081881A2 (fr) 2020-04-23
JP2022512722A (ja) 2022-02-07
CN113195540A (zh) 2021-07-30
US20200121588A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
EP3447137A4 (fr) Préparation d'enzyme liquide et son procédé de préparation
EP3315512A4 (fr) Procédé pour la préparation sélective d'un conjugué anticorps-médicament
EP3393647A4 (fr) Procédé d'encapsulation de composés biologiques, thérapeutiques et d'agents d'imagerie solubles
MA49394A (fr) Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps
EP4000601A4 (fr) Préparation d'injection d'ast-3424 stable et procédé de préparation
EP3683205A4 (fr) Procédé de préparation d'isocyanate aliphatique
EP3398939A4 (fr) Dérivé d'acrylanilide, son procédé de préparation et ses applications en pharmacie
EP3516713A4 (fr) Procédé de préparation d'ensembles d'électrodes
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3824897A4 (fr) Composition de médicine traditionnelle chinoise et son procédé de préparation et d'application
EP3927701A4 (fr) Procédé de préparation de diamides anthraniliques et d'intermédiaires correspondants
EP3734268A4 (fr) Procédé simplifié de quantification d'anticorps monoclonaux
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
EP3808732A4 (fr) Procédé de préparation d'isocyanates aliphatiques
EP4005561A4 (fr) Préparation nanomicellaire d'icaritine et son procédé de préparation et son application
EP4015519A4 (fr) Procédé de préparation d'asénapine
EP3970744A4 (fr) Injection stable de secukinumab et procédé pour sa préparation
EP3782674A4 (fr) Procédé d'amorçage d'ensemble de perfusion et ensemble de perfusion
EP3902792A4 (fr) Procédé de préparation d'anthranilamides
EP3644335A4 (fr) Procédé de préparation d'un matériau actif d'anode pour pseudo-condensateur
EP3432925A4 (fr) Administration d'un anticorps monoclonal anti-lgr5
EP3878435A4 (fr) Préparation de liposomes d'irinotécan, procédé de préparation et application associées
EP3932400A4 (fr) Inhalant de type solution de péramivir et son procédé de préparation
EP3369426A4 (fr) Procédé pour augmenter la production de lymphocytes t cytotoxiques (ctl) spécifiques pour un antigène et d'anticorps
EP3421521A4 (fr) Procédé de préparation d'un dérivé de polyéthylène glycol dialdéhyde